Johnson & Johnson Withdraws LINX Reflux Management System from International Markets, Citing Strategic Realignment

Yesterday (On September 23, 2025, Johnson & Johnson announced that, after a comprehensive evaluation of market conditions and service capabilities, the company has decided to discontinue the sale of the LINX Reflux Management System, a product used to treat debilitating gastroesophageal reflux disease, in countries outside the United States.

Surgeons have warned that,Linx Currently Has No Direct Alternative, and the Discontinuation of This Device Will Set Back the Available Treatment Options for Patients with Gastroesophageal Reflux Disease (GERD) by More Than a Decade. It May Also Impact Lung Transplant Patients, Who Often Require GERD Treatment to Prevent Rejection of the Transplanted Organ. In Some Cases, the Linx Device Is Used Specifically for This Purpose.

Johnson & Johnson spokesperson clearly stated that this withdrawal is"The choice made after a comprehensive evaluation of market conditions and the ability to effectively serve various markets"，This decision is based on commercial considerations and is unrelated to device safety.。

From the perspective of technical principles and applications,The LINX Reflux Management System is a medical device specifically designed to treat gastroesophageal reflux disease (GERD), a condition where stomach contents abnormally flow back into the esophagus. At its core is a flexible ring structure composed of small magnetic beads, which, when implanted around the lower esophageal sphincter, uses magnetic force to help keep the sphincter closed, effectively preventing acid reflux. For patients with chronic GERD, LINX offers a more refined surgical solution that better balances the need for "effective reflux control" with "preserving normal physiological function" compared to traditional anti-reflux surgeries.

It is worth noting that,Based onThe safety and effectiveness of the LINX device have not changed.ThereforeThe U.S. market is not affected by this adjustment.—— Patients and doctors in the United States can still use the device normally.

In fact, Johnson & Johnson received approval from the U.S. Food and Drug Administration (FDA) last year.FDA) approved the updated labeling for the LINX system, expanding its indicated patient population to include those with Barrett's esophagus suffering from reflux symptoms. This "U.S.-market-exclusive" differentiation strategy also indirectly reflects Johnson & Johnson's recognition of the profitability and business environment in the U.S. market.

Johnson & Johnson's decision, in essence, is a multinational enterprise"Focus on Core Markets" Reflects Global Operation Strategy. A company spokesperson explained: "We continuously evaluate our surgical technology portfolio with the aim of focusing on areas where patients have significant unmet needs, and driving the implementation of the most innovative technologies." By withdrawing from certain non-core markets, Johnson & Johnson can concentrate resources on business areas and regions with greater growth potential, thereby optimizing its product portfolio and enhancing overall operational efficiency.

However, this adjustment will also have a direct impact on patients in non-U.S. regions: in the future, patients with chronic gastroesophageal reflux disease in these regions may need to seekAlternative treatment options outside of the LINX device. For Johnson & Johnson, this contraction does not alter its position in the U.S. medical device market; whether it will reassess its global market strategy in the future still depends on changes in regional market conditions and adjustments to the company’s strategic direction.

British Surgical ExpertMajid Hashemi frankly stated, "This is devastating news." As an expert specializing in anti-reflux surgery, he pointed out that LINX has become a "default surgical option," and its discontinuation will lead to patients losing an important choice. He said that Johnson & Johnson had contacted him directly to inform him of their decision.

Currently, regardingJohnson & Johnson has not yet provided detailed information on the specific countries LINX will withdraw from or the complete timeline.According to foreign media reportsThe content of the letter sent by Johnson & Johnson to doctors pointed out that the company plans toStarting from March 2026, the LINX device will be gradually withdrawn from non-U.S. markets.